{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:09:50Z","timestamp":1792177790188,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Continuous renal replacement techniques (CRRT) can induce complications and monitoring is crucial to ensure patient safety. We designed a prospective multicenter observational and descriptive study using the DIALYREG registry, an online database located on a REDCap web-based platform that allows real-time data analysis. Our main objective was to identify CRRT-related complications in our intensive care units (ICUs) and implement security measures accordingly. From January 2019 to December 2020, we included 323 patients with admission diagnoses of medical illness (54%), sepsis (24%), postoperative care (20%), and trauma (2%). CRRT indications were homeostasis (42%), oliguria (26%), fluid overload (15%), and hemodynamic optimization (13%). The median initial therapy dose was 30\u00a0ml\/kg\/h (IQR 25\u201340), and dynamic adjustment was performed in 61% of the treatments. Sets were anticoagulated with heparin (40%), citrate (38%) or no anticoagulation (22%). Citrate anticoagulation had several advantages: more frequent dynamic CRRT dose adjustment (77% vs. 58% with heparin and 56% without anticoagulation, p\u2009&lt;\u20090.05), longer duration of set (median of 55\u00a0h, IQR 24\u201372 vs. 23\u00a0h, IQR 12\u201348 with heparin and 12\u00a0h, IQR 12\u201331 without anticoagulation, p\u2009&lt;\u20090.05), less clotting of the set (26% vs. 46.7% with heparin, p\u2009&lt;\u20090.05), and lower incidence of hypophosphatemia (1% citrate vs. 6% with heparin and 5% without anticoagulation). It was also safe and effective in subgroup analysis of patients with liver disease or sepsis. The main global complications were hypothermia (16%), hypophosphatemia (13%) and metabolic acidosis (10%). Weaning of the therapy was achieved through early discontinuation (56%), nocturnal therapy transition (26%) and progressive SLED (18%). 52% of the patients were discharged from the hospital, while 43% died in the ICU and 5% died during hospitalization. We can conclude that the DIALYREG registry is a feasible tool for real-time control of CRRT in our ICU.<\/jats:p>","DOI":"10.1038\/s41598-023-32795-y","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T17:01:26Z","timestamp":1682010086000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluation of the registry DIALYREG for the assessment of continuous renal replacement techniques in the critically ill patient"],"prefix":"10.1038","volume":"13","author":[{"given":"M.","family":"Gonz\u00e1lez-Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Qu\u00edlez-Trasobares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Barea-Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Molina-Collado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Arias-Verd\u00fa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Barrueco-Francioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Seller-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Herrera-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"S\u00e1nchez-Izquierdo Riera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"32795_CR1","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","volume":"41","author":"E Hoste","year":"2015","unstructured":"Hoste, E. et al. Epidemiology of acute kidney injury in critically ill patients: The multinational AKI-EPI study. Intens. Care Med. 41, 1411\u20131423 (2015).","journal-title":"Intens. Care Med."},{"key":"32795_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.jcrc.2013.05.019","volume":"28","author":"ME Herrera-Guti\u00e9rrez","year":"2013","unstructured":"Herrera-Guti\u00e9rrez, M. E., Seller-p\u00e9rez, G., S\u00e1nchez-izquierdo-riera, J. A. & Maynar-moliner, J. Prevalence of acute kidney injury in intensive care units: The \u201cCOrte de prevalencia de disFunci\u00f3n RenAl y DEpuraci\u00f3n en cr\u00edticos\u201d point-prevalence multicenter study. J. Crit. Care 28, 687\u2013694 (2013).","journal-title":"J. Crit. Care"},{"key":"32795_CR3","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s00467-013-2594-5","volume":"29","author":"SM Sutherland","year":"2014","unstructured":"Sutherland, S. M., Goldstein, S. L. & Alexander, S. R. The prospective pediatric continuous renal replacement therapy (ppCRRT) registry: A critical appraisal. Pediatr. Nephrol. 29, 2069\u20132076 (2014).","journal-title":"Pediatr. Nephrol."},{"key":"32795_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000342064","volume":"34","author":"J Maynar Moliner","year":"2012","unstructured":"Maynar Moliner, J., Honore, P. M., Sanchez-Izquierdo Riera, J. A., Herrera Gutierrezx, M. E. & Spape, H. D. Handling continuous renal replacement therapy-related adverse effects in intensive care unit patients: The dialytrauma concept. Blood Purif. 34, 177\u2013185 (2012).","journal-title":"Blood Purif."},{"issue":"2","key":"32795_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris, P. A. et al. Research electronic data capture (REDCap) a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inf. 42(2), 377\u2013381 (2009).","journal-title":"J. Biomed. Inf."},{"issue":"9223","key":"32795_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S0140-6736(00)02430-2","volume":"356","author":"C Ronco","year":"2000","unstructured":"Ronco, C. et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: A prospective randomised trial. Lancet 356(9223), 26\u201330 (2000).","journal-title":"Lancet"},{"issue":"10","key":"32795_CR7","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1097\/00003246-200210000-00005","volume":"30","author":"CS Bouman","year":"2002","unstructured":"Bouman, C. S. et al. Effects of early high volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: A prospective, randomized trial. Crit. Care Med. 30(10), 2205\u20132211 (2002).","journal-title":"Crit. Care Med."},{"issue":"6","key":"32795_CR8","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1681\/ASN.2007111173","volume":"19","author":"AJ Tolwani","year":"2008","unstructured":"Tolwani, A. J. et al. Standard versus highdose CVVHDF for ICU-related acute renal failure. J. Am. Soc. Nephrol. 19(6), 1233\u20131238 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"32795_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1056\/NEJMoa0802639","volume":"359","author":"PM Palevsky","year":"2008","unstructured":"Palevsky, P. M. et al. VA\/NIH acute renal failure trial network: Intensity of renal support in critically ill patients with acute kidney injury. N. Engl. J. Med. 359(1), 7\u201320 (2008).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"32795_CR10","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1097\/CCM.0b013e3181d9d912","volume":"38","author":"R Van Wert","year":"2010","unstructured":"Van Wert, R. et al. High-dose renal replacement therapy for acute kidney injury: Systematic review and meta-analysis. Crit. Care Med. 38(5), 1360\u20131369 (2010).","journal-title":"Crit. Care Med."},{"key":"32795_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"Kidney Disease Improving Global Outcome KDIGO","year":"2012","unstructured":"Kidney Disease Improving Global Outcome KDIGO. Acute kidney injury work group: KDIGO clinical practice guideline for acute kidney injury. Kidney Int. Suppl. 2, 1\u2013138 (2012).","journal-title":"Kidney Int. Suppl."},{"issue":"6","key":"32795_CR12","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1046\/j.1523-1755.2000.00439.x","volume":"58","author":"MJ Oliver","year":"2000","unstructured":"Oliver, M. J., Callery, S. M., Thorpe, K. E., Schwab, S. J. & Churchill, D. N. Risk of bacteremia from temporary hemodialysis catheters by site of insertion and duration of use: A prospective study. Kidney Int. 58(6), 2543\u20132545 (2000).","journal-title":"Kidney Int."},{"issue":"20","key":"32795_CR13","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1001\/jama.299.20.2413","volume":"299","author":"JJ Parienti","year":"2008","unstructured":"Parienti, J. J. et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: A randomized controlled trial. JAMA 299(20), 2413\u20132422 (2008).","journal-title":"JAMA"},{"issue":"6","key":"32795_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/MCC.0000000000000547","volume":"24","author":"D Kindgen-Milles","year":"2018","unstructured":"Kindgen-Milles, D., Brandenburger, T. & Dimski, T. Regional citrate anticoagulation for continuous renal replacement therapy. Curr. Opin. Crit. Care 24(6), 450\u2013454 (2018).","journal-title":"Curr. Opin. Crit. Care"},{"key":"32795_CR15","first-page":"602","volume":"20","author":"MG Betjes","year":"2007","unstructured":"Betjes, M. G., van Oosterom, D., van Agteren, M. & van de Wetering, J. Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: Similar hemofilter survival but significantly less bleeding. J. Nephrol. 20, 602\u2013608 (2007).","journal-title":"J. Nephrol."},{"key":"32795_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/sdi.12923","volume":"34","author":"L Li","year":"2021","unstructured":"Li, L. et al. Regional citrate anticoagulation vs no-anticoagulation for CRRT in hyperlactatemia patients with increased bleeding risk: A retrospective cohort study. Semin. Dial. 34, 209\u2013217 (2021).","journal-title":"Semin. Dial."},{"key":"32795_CR17","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/ndt\/gfh817","volume":"20","author":"PD Brophy","year":"2005","unstructured":"Brophy, P. D. et al. Multicentre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol. Dial. Transpl. 20, 1416\u20131421 (2005).","journal-title":"Nephrol. Dial. Transpl."},{"key":"32795_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13054-017-1880-1","volume":"21","author":"AG Schneider","year":"2017","unstructured":"Schneider, A. G., Journois, D. & Rimmel\u00e9, T. Complications of regional citrate anticoagulation: Accumulation or overload? Crit. Care 21, 281 (2017).","journal-title":"Crit. Care"},{"key":"32795_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1053\/j.gastro.2019.03.070","volume":"157","author":"J O\u2019Learly","year":"2019","unstructured":"O\u2019Learly, J., Greenberg, C., Patton, H. & Caldwell, S. AGA clinical practice update: Coagulation in cirrhosis. Gastroenterology 157, 34\u201343 (2019).","journal-title":"Gastroenterology"},{"issue":"1","key":"32795_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13054-019-2317-9","volume":"23","author":"W Zhang","year":"2019","unstructured":"Zhang, W. et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: A systematic review and meta-analysis. Crit. Care 23(1), 22 (2019).","journal-title":"Crit. Care"},{"key":"32795_CR21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s13054-017-1870-3","volume":"21","author":"M Klingele","year":"2017","unstructured":"Klingele, M. et al. Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction. Crit. Care 21, 294 (2017).","journal-title":"Crit. Care"},{"key":"32795_CR22","doi-asserted-by":"publisher","first-page":"R162","DOI":"10.1186\/cc11485","volume":"16","author":"C Schultheiss","year":"2012","unstructured":"Schultheiss, C. et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: A prospective observational study. Crit. Care 16, R162 (2012).","journal-title":"Crit. Care"},{"key":"32795_CR23","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.jcrc.2015.06.006","volume":"30","author":"T Lahmer","year":"2015","unstructured":"Lahmer, T. et al. Sustained low-efficiency dialysis with regional citrate anticoagulation in medical intensive care unit patients with liver failure: A prospective study. J. Crit. Care 30, 1096\u20131100 (2015).","journal-title":"J. Crit. Care"},{"key":"32795_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s13054-015-1066-7","volume":"19","author":"T Slowinski","year":"2015","unstructured":"Slowinski, T. et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: The liver citrate anticoagulation threshold (L-CAT) observational study. Crit. Care 19, 349 (2015).","journal-title":"Crit. Care"},{"key":"32795_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13054-019-2317-9","volume":"23","author":"Zhang","year":"2019","unstructured":"Zhang, et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: A systematic review and meta-analysis. Crit. Care 23, 22 (2019).","journal-title":"Crit. Care"},{"key":"32795_CR26","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J. Hepatol. 69, 406\u2013460 (2018).","journal-title":"J. Hepatol."},{"key":"32795_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi, Z. et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"32795_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/MCC.0000000000000590","volume":"25","author":"A MacDonald","year":"2019","unstructured":"MacDonald, A., Nadim, M., Durand, F. & Karvellas, C. Acute kidney injury in cirrhosis: Implications for liver transplantation. Curr. Opin. Crit. Care 25(2), 171\u2013178 (2019).","journal-title":"Curr. Opin. Crit. Care"},{"issue":"5","key":"32795_CR29","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.kint.2017.04.048","volume":"92","author":"A Davenport","year":"2017","unstructured":"Davenport, A., Sheikh, M., Lamb, E., Agarwal, B. & Jalan, R. Acute kidney injury in acute-on-chronic liver failure: Where does hepatorenal syndrome fit? Kidney Int. 92(5), 1058\u20131070 (2017).","journal-title":"Kidney Int."},{"key":"32795_CR30","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1038\/s41598-022-05867-8","volume":"12","author":"P Thanapongsatorn","year":"2022","unstructured":"Thanapongsatorn, P. et al. Citrate pharmacokinetics in critically ill liver failure patients receiving CRRT. Sci. Rep. 12, 1815 (2022).","journal-title":"Sci. Rep."},{"key":"32795_CR31","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1007\/s001340000691","volume":"26","author":"HK Tan","year":"2000","unstructured":"Tan, H. K., Baldwin, I. & Bellomo, R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. Intens. Care Med. 26, 1652\u20131657 (2000).","journal-title":"Intens. Care Med."},{"issue":"12","key":"32795_CR32","first-page":"2098","volume":"41","author":"M Bai","year":"2015","unstructured":"Bai, M. et al. Citrate versus heparin anticoagulation for continuous renal replacement therapy: An updated meta-analysis of RCTs. ICM 41(12), 2098\u20132110 (2015).","journal-title":"ICM"},{"key":"32795_CR33","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13054-016-1299-0","volume":"20","author":"C Liu","year":"2016","unstructured":"Liu, C. et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: A meta-analysis with trial sequential analysis of randomized controlled trials. Crit. Care 20, 144 (2016).","journal-title":"Crit. Care"},{"key":"32795_CR34","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/ndt\/gfq575","volume":"26","author":"GR Hetzel","year":"2011","unstructured":"Hetzel, G. R. et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: A prospective randomized multicentre trial. Nephrol. Dial. Transplant 26, 232\u2013239 (2011).","journal-title":"Nephrol. Dial. Transplant"},{"key":"32795_CR35","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/CCM.0b013e3181953c5e","volume":"37","author":"HM Oudemans-van Straaten","year":"2009","unstructured":"Oudemans-van Straaten, H. M. et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit. Care Med. 37, 545\u2013552 (2009).","journal-title":"Crit. Care Med."},{"key":"32795_CR36","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s00134-003-2047-x","volume":"30","author":"M Monchi","year":"2004","unstructured":"Monchi, M. et al. Citrate vs heparin for anticoagulation in continuous venovenous hemofiltration: A prospective randomized study. Intens. Care Med. 30, 260\u2013265 (2004).","journal-title":"Intens. Care Med."},{"key":"32795_CR37","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1111\/j.1523-1755.2005.00342.x","volume":"67","author":"DJ Kutsogiannis","year":"2005","unstructured":"Kutsogiannis, D. J., Gibney, R. T., Stollery, D. & Gao, J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int. 67, 2361\u20132367 (2005).","journal-title":"Kidney Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32795-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32795-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32795-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T17:04:24Z","timestamp":1682010264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32795-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["32795"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-32795-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"14 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6479"}}